IMvigor011: A global, double-blind, randomised phase III study of   atezolizumab (atezo; anti-PD-L1) vs placebo (pbo) as adjuvant therapy in   patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who   are circulating tumour (ct)DNA plus post cystectomy

Document type:: Meeting Abstract
Author(s):: Powles, T. B.; Gschwend, J. E.; Bracarda, S.; Castellano, D.; Gross-Goupil, M.; Jensen, J. Bjerggaard; Kann, A.; Nishiyama, H.; Makaroff, L.; Lassidi, H.; Mariathasan, S.; Zhang, J.; Degaonkar, V.; Bellmunt, J.
Title:: IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti-PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA plus post cystectomy
Journal title abbreviation:: Ann Oncol
Year:: 2021
Journal volume:: 32 Suppl 5
Pages contribution:: S721-S721
Fulltext / DOI:: doi:10.1016/j.annonc.2021.08.112
Print-ISSN:: 0923-7534
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: